Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mol Carcinog ; 63(4): 647-662, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38197491

RESUMO

Colorectal cancer (CRC) continues to be a prevalent malignancy, posing a significant risk to human health. The involvement of alpha/beta hydrolase domain 6 (ABHD6), a serine hydrolase family member, in CRC development was suggested by our analysis of clinical data. However, the role of ABHD6 in CRC remains unclear. This study seeks to elucidate the clinical relevance, biological function, and potential molecular mechanisms of ABHD6 in CRC. We investigated the role of ABHD6 in clinical settings, conducting proliferation, migration, and cell cycle assays. To determine the influence of ABHD6 expression levels on Oxaliplatin sensitivity, we also performed apoptosis assays. RNA sequencing and KEGG analysis were utilized to uncover the potential molecular mechanisms of ABHD6. Furthermore, we validated its expression levels using Western blot and reactive oxygen species (ROS) detection assays. Our results demonstrated that ABHD6 expression in CRC tissues was notably lower compared to adjacent normal tissues. This low expression correlated with a poorer prognosis for CRC patients. Moreover, ABHD6 overexpression impeded CRC cell proliferation and migration while inducing G0/G1 cell cycle arrest. In vivo experiments revealed that downregulation of ABHD6 resulted in an increase in tumor weight and volume. Mechanistically, ABHD6 overexpression inhibited the activation of the AKT signaling pathway and decreased ROS levels in CRC cells, suggesting the role of ABHD6 in CRC progression via the AKT signaling pathway. Our findings demonstrate that ABHD6 functions as a tumor suppressor, primarily by inhibiting the AKT signaling pathway. This role establishes ABHD6 as a promising prognostic biomarker and a potential therapeutic target for CRC patients.


Assuntos
Neoplasias Colorretais , Proteínas Proto-Oncogênicas c-akt , Humanos , Espécies Reativas de Oxigênio , Proliferação de Células , Pontos de Checagem da Fase G1 do Ciclo Celular , Hidrolases , Transdução de Sinais , Neoplasias Colorretais/genética , Linhagem Celular Tumoral , Movimento Celular , Monoacilglicerol Lipases
2.
Cell Metab ; 35(9): 1580-1596.e9, 2023 09 05.
Artigo em Inglês | MEDLINE | ID: mdl-37506695

RESUMO

Metabolic reprogramming toward glycolysis is a hallmark of cancer malignancy. The molecular mechanisms by which the tumor glycolysis pathway promotes immune evasion remain to be elucidated. Here, by performing genome-wide CRISPR screens in murine tumor cells co-cultured with cytotoxic T cells (CTLs), we identified that deficiency of two important glycolysis enzymes, Glut1 (glucose transporter 1) and Gpi1 (glucose-6-phosphate isomerase 1), resulted in enhanced killing of tumor cells by CTLs. Mechanistically, Glut1 inactivation causes metabolic rewiring toward oxidative phosphorylation, which generates an excessive amount of reactive oxygen species (ROS). Accumulated ROS potentiate tumor cell death mediated by tumor necrosis factor alpha (TNF-α) in a caspase-8- and Fadd-dependent manner. Genetic and pharmacological inactivation of Glut1 sensitizes tumors to anti-tumor immunity and synergizes with anti-PD-1 therapy through the TNF-α pathway. The mechanistic interplay between tumor-intrinsic glycolysis and TNF-α-induced killing provides new therapeutic strategies to enhance anti-tumor immunity.


Assuntos
Neoplasias , Fator de Necrose Tumoral alfa , Camundongos , Animais , Humanos , Fator de Necrose Tumoral alfa/metabolismo , Transportador de Glucose Tipo 1 , Evasão da Resposta Imune , Espécies Reativas de Oxigênio/metabolismo , Glicólise , Linfócitos T/metabolismo , Linhagem Celular Tumoral
3.
Biomicrofluidics ; 16(3): 034102, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-35547183

RESUMO

The mechanical properties of cells are of great significance to their normal physiological activities. The current methods used for the measurement of a cell's mechanical properties have the problems of complicated operation, low throughput, and limited measuring range. Based on micropipette technology, we designed a double-layer micro-valve-controlled microfluidic chip with a series of micropipette arrays. The chip has adjustment pressure ranges of 0.03-1 and 0.3-10 kPa and has a pressure stabilization design, which can achieve a robust measurement of a single cell's mechanical properties under a wide pressure range and is simple to operate. Using this chip, we measured the mechanical properties of the cells treated with different concentrations of paraformaldehyde (PFA) and observed that the viscoelasticity of the cells gradually increased as the PFA concentration increased. Then, this method was also used to characterize the changes in the mechanical properties of the differentiation pathways of stem cells from the apical papilla to osteogenesis.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA